Retifanlimab
Non-Small Cell Lung Carcinoma
University of California, San Diegomonoclonal antibodyPhase 3
—
Rating in progress
Retifanlimab in Non-Small Cell Lung Carcinoma is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.
Methodology v0.2 · Active